Why the study?
Do rare genetic variants predispose individuals to statin-associated myopathy?
Do rare genetic variants predispose individuals to statin-associated myopathy?
Rare genetic variants, including a truncating mutation in CLCN1, may predispose individuals to statin-associated myopathy.
Rare variant analysis in statin myopathy remains hypothesis-generating; larger studies needed before any clinical genetic testing expansion.
AIM: Genetic variants affecting statin uptake, metabolism or predisposing to muscular diseases may confer susceptibility to statin-induced myopathy. Besides the SLCO1B1 rs4149056 genotype, common genetic variants do not seem to determine statin-associated myopathy. Here we aimed to address the potential role of rare variants. METHODS: We performed whole exome sequencing in 88 individuals suffering from statin-associated myopathy and assessed the burden of rare variants using candidate-gene and exome-wide association analysis. RESULTS: In the novel candidate gene CLCN1, we identified a heterozygote truncating mutation p.R894* in four patients. In addition, we detected predictably pathogenic case-specific variants in MYOT, CYP3A5, SH3TC2, FBXO32 and RBM20. CONCLUSION: These findings support the role of rare variants and nominate loci for follow-up studies.
No takes yet. Share an insight, caveat, or question.
Neřoldová et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: